A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects

2024-516197-30-00 Protocol NAT-022/BIO Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 16 Jul 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 3 sites · Protocol NAT-022/BIO

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 60
Countries 3
Sites 3

Idiopathic or diabetic gastroparesis

Key facts

Sponsor
Dr. Falk Pharma GmbH
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
16 Jul 2025 → ongoing
Decision date (initial)
2025-08-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Idiopathic or diabetic gastroparesis

VersionLevelCodeTermSystem organ class
20.1 LLT 10021227 Idiopathic gastroparesis 10017947
20.0 LLT 10018043 Gastroparesis 10017947
20.1 PT 10051153 Diabetic gastroparesis 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Dr. Falk Pharma GmbH

Sponsor organisation
Dr. Falk Pharma GmbH
Address
Leinenweberstrasse 5, Hochdorf Hochdorf
City
Freiburg Im Breisgau
Postcode
79108
Country
Germany

Scientific contact point

Organisation
Dr. Falk Pharma GmbH
Contact name
CTIS – Scientific Request

Public contact point

Organisation
Dr. Falk Pharma GmbH
Contact name
Clinical Research and Development

Locations

3 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 10 1
Germany Ongoing, recruiting 24 1
Poland Ongoing, recruiting 26 1
Rest of world 0

Investigational sites

Belgium

1 site · Ongoing, recruiting
UZ Leuven
Gastroenterology, Herestraat 49, 3000, Leuven

Germany

1 site · Ongoing, recruiting
SocraTec R&D Concepts in Drug Research and Development GmbH
CPU, Mainzerhofplatz 14, Erfurt-Altstadt, Erfurt

Poland

1 site · Ongoing, recruiting
Biokinetica S.A.
n.a., Ul. Nadwislanska 37, 05-410, Jozefow

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-10-09 2025-12-17
Germany 2025-07-16 2025-08-25
Poland 2025-10-01 2025-11-03

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-12 Germany Acceptable
2025-04-17
2025-04-25
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-04 Germany Acceptable
2025-04-17
2025-06-04
3 SUBSTANTIAL MODIFICATION SM-1 2025-06-05 Germany Acceptable 2025-06-30
4 SUBSEQUENT ADDITION OF MSC APP-4 2025-07-03 Acceptable
2025-04-17
2025-08-26
5 SUBSEQUENT ADDITION OF MSC APP-5 2025-07-04 Acceptable
2025-04-17
2025-09-27
6 SUBSTANTIAL MODIFICATION SM-4 2025-12-19 Germany Acceptable
2026-02-27
2026-03-02